{"gene":"BCL2L14","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2000,"finding":"BCL-G encodes two isoforms (BCL-GL and BCL-GS) via alternative splicing; BCL-GS contains only a BH3 domain while BCL-GL contains both BH2 and BH3 domains. BCL-GS-induced apoptosis depends on its BH3 domain and is suppressed by BCL-XL co-expression. BCL-XL co-immunoprecipitates with BCL-GS but not with BH3-deleted/mutated BCL-GS or with BCL-GL. Deletion of the BH2 domain from BCL-GL increases its apoptotic activity and enables co-immunoprecipitation with BCL-XL, indicating BH2 autorepresses BCL-GL. BCL-GS localizes to cytosolic organelles; BCL-GL is diffusely distributed in the cytosol.","method":"Overexpression in cells, co-immunoprecipitation, BH3 domain deletion/mutation, subcellular localization, apoptosis assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (co-IP, mutagenesis, localization, functional apoptosis assay) in the discovery paper; foundational study replicated in subsequent work","pmids":["11054413"],"is_preprint":false},{"year":2007,"finding":"MELK kinase physically interacts with BCL-GL through its amino-terminal region (pull-down assay), and BCL-GL is specifically phosphorylated by MELK in vitro (immunocomplex kinase assay). Overexpression of wild-type MELK suppresses BCL-GL-induced apoptosis, while kinase-dead MELK (D150A) does not, demonstrating that MELK's kinase activity is required to inhibit BCL-GL pro-apoptotic function.","method":"Pull-down assay with recombinant wild-type and kinase-dead MELK, immunocomplex kinase assay, TUNEL and FACS apoptosis analysis, RNAi knockdown","journal":"Breast cancer research : BCR","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — in vitro kinase assay plus mutagenesis (kinase-dead mutant) plus functional apoptosis readout in a single study","pmids":["17280616"],"is_preprint":false},{"year":2011,"finding":"FAU (encoding ubiquitin-like protein FUBI) promotes apoptosis in human T-cell lines and 293T/17 cells; prior knockdown of BCL-G expression ablates FAU-stimulated basal apoptosis, placing BCL-G downstream of FAU in the same apoptotic pathway. UV irradiation also increases BCL-G mRNA levels and BCL-G knockdown attenuates UV-induced apoptosis, implicating BCL-G as a common mediator of FAU- and UV-induced apoptosis.","method":"siRNA-mediated knockdown (FAU and BCL-G), ectopic FAU overexpression, apoptosis quantification in T-cell lines and 293T/17 cells, RT-PCR","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis via RNAi knockdown with specific apoptosis phenotype, two orthogonal perturbations (OE and KD), single lab","pmids":["21550398"],"is_preprint":false},{"year":2012,"finding":"Mouse BCL-G binds only weakly to pro-survival BCL-2 family members in a BH3-domain-independent manner. Immunoprecipitation/mass spectrometry and yeast two-hybrid screening identified proteins of the transport particle protein (TRAPP) complex as BCL-G-binding partners, suggesting BCL-G has a role in intracellular protein trafficking rather than classical stress-induced apoptosis. BCL-G knockout mice show no apparent apoptotic defects.","method":"Immunoprecipitation/mass spectrometry, yeast two-hybrid screening, BCL-G knockout mouse generation, co-immunoprecipitation","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and MS interactome plus KO mouse with phenotypic readout, single lab, two orthogonal methods","pmids":["23059823"],"is_preprint":false},{"year":2013,"finding":"Ubiquitin-like protein MNSFβ covalently binds to BCL-G in mouse macrophages (Raw264.7). Co-transfection of MNSFβ and BCL-G greatly enhances LPS/IFNγ-induced apoptosis, accompanied by increased p53 expression and decreased COX-2 activity. MNSFβ G74A mutant (unable to covalently conjugate) fails to enhance apoptosis with BCL-G. The MNSFβ-BCL-G complex down-regulates ERK/AP-1 signaling, reducing COX-2 activation.","method":"Co-transfection, siRNA knockdown of MNSFβ, MNSFβ G74A mutant, apoptosis assays (TUNEL, flow cytometry), EMSA, western blot for p53/COX-2/ERK","journal":"The FEBS journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mutagenesis (G74A) combined with co-transfection and signaling readouts in a single lab study with multiple orthogonal methods","pmids":["23298187"],"is_preprint":false},{"year":2019,"finding":"BCL-G is highly expressed in gastrointestinal epithelial cells from early embryonic development and is dispensable for normal growth and development in mice. However, loss of BCL-G accelerates colitis-associated colorectal cancer progression. Label-free quantitative proteomics revealed that BCL-G contributes to the stability of a mucin scaffolding network in the gut epithelium.","method":"Bcl-G knockout mouse model, colitis-associated cancer model, label-free quantitative proteomics, immunohistochemistry","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mouse with defined cancer phenotype plus proteomics identification of mucin network interaction, multiple orthogonal methods","pmids":["31296963"],"is_preprint":false},{"year":2020,"finding":"BCL-G is dispensable for IFN-γ/TNF-α-induced apoptosis in intestinal epithelial cells (IEC), as shown by RNAi and CRISPR/Cas9 perturbations. Instead, BCL-G depletion differentially affects secretion of inflammatory chemokines CCL5 and CCL20, revealing a non-apoptotic immunoregulatory function. Optimal BCL-G expression requires STAT1, NF-κB/p65, and SWI/SNF-associated chromatin remodellers BRM and BRG1.","method":"RNAi knockdown, CRISPR/Cas9 knockout, isoform-specific overexpression, chemokine secretion assays, primary human colonic organoids, pathway inhibition","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR KO and RNAi with specific chemokine secretion readout, multiple orthogonal perturbations including primary organoids","pmids":["31988296"],"is_preprint":false},{"year":2020,"finding":"BCL2L14-ETV6 fusion proteins (arising from cryptic adjacent gene rearrangement) induce distinct transcriptional changes compared to wild-type ETV6, enhance cell motility and invasiveness of TNBC cells, prime partial epithelial-mesenchymal transition, and confer resistance to paclitaxel treatment.","method":"Ectopic expression of fusion constructs, cell motility/invasion assays, gene expression analysis, paclitaxel resistance assays, whole-genome sequencing of patient cohorts","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional cell-based assays with ectopic fusion expression, multiple readouts, single lab","pmids":["32321829"],"is_preprint":false},{"year":2018,"finding":"BCL-G overexpression diminishes HIV replication in vitro, and RNAi to BCL-G attenuates the IFN-α2b-mediated restriction of HIV in culture, identifying BCL-G as an interferon-stimulated gene (ISG) with antiviral activity against HIV.","method":"RNA interference knockdown, BCL-G overexpression, in vitro HIV replication assay, IFN-α2b treatment","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — both gain- and loss-of-function experiments with specific viral replication readout, single lab, two orthogonal methods","pmids":["30083606"],"is_preprint":false},{"year":2016,"finding":"Porcine BCL-G interacts with porcine JAB1 (CSN5); this interaction affects BCL-G subcellular distribution and significantly enhances staurosporine-induced apoptosis that is at least partially dependent on activated caspase-8, -9, and -3. The BH2 domain of BCL-G affects its subcellular localization.","method":"Co-immunoprecipitation, subcellular localization analysis, overexpression, caspase activity assays, apoptosis assays","journal":"Oncotarget","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single co-IP with functional follow-up in porcine (non-mammalian-model) cells, single lab, ortholog relevance to human BCL-G uncertain","pmids":["27542239"],"is_preprint":false},{"year":2012,"finding":"Mouse BCL-G is predominantly cytoplasmic and is expressed in mature spermatids in the testis, CD8+ conventional dendritic cells in hematopoietic tissues, and diverse epithelial cell types lining the gastrointestinal and respiratory tracts.","method":"Monoclonal antibody generation, western blotting, immunohistochemistry, immunofluorescence","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization via multiple antibody-based methods (IHC, IF, WB) with tissue-level resolution","pmids":["22914326"],"is_preprint":false},{"year":2025,"finding":"Overexpression of BCL2L14 in breast cancer cells accelerates cancer cell proliferation/progression, linked to enhanced phosphorylation of the NF-κB signaling pathway.","method":"In vitro BCL2L14 overexpression, downstream NF-κB phosphorylation assay","journal":"Journal of inflammation research","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single overexpression experiment with signaling readout, single lab, minimal mechanistic detail in abstract","pmids":["40491783"],"is_preprint":false}],"current_model":"BCL-G (BCL2L14) is a BCL-2 family protein existing as two isoforms (BCL-GL with BH2+BH3 domains; BCL-GS with BH3 only) whose pro-apoptotic activity is mediated through its BH3 domain (interacting with BCL-XL), autorepressed by its BH2 domain in BCL-GL, and regulated by post-translational modifications including covalent conjugation by ubiquitin-like MNSFβ and phosphorylation by MELK kinase; beyond apoptosis, BCL-G plays roles in intracellular protein trafficking (via interaction with the TRAPP complex), gut epithelial homeostasis through maintaining a mucin scaffolding network, and immunomodulation through regulation of CCL5/CCL20 chemokine secretion, while also functioning as an interferon-stimulated antiviral factor."},"narrative":{"mechanistic_narrative":"BCL2L14 (BCL-G) is a BCL-2 family protein originally characterized as a pro-apoptotic factor but increasingly defined by non-apoptotic roles in epithelial homeostasis, immune regulation, and antiviral defense [PMID:11054413, PMID:31296963, PMID:31988296]. It is expressed as two splice isoforms: BCL-GS, a BH3-only protein whose apoptotic activity depends on its BH3 domain and is suppressed by BCL-XL, with which it directly co-immunoprecipitates; and the longer BCL-GL, in which an additional BH2 domain autorepresses pro-apoptotic activity and blocks BCL-XL binding until removed [PMID:11054413]. Its death-promoting function is gated by post-translational control — MELK kinase binds and phosphorylates BCL-GL to inhibit its apoptotic activity [PMID:17280616], while covalent conjugation by the ubiquitin-like protein MNSFβ enhances LPS/IFNγ-induced apoptosis through down-regulation of ERK/AP-1 and COX-2 signaling [PMID:23298187]. In vivo, however, BCL-G is dispensable for stress-induced apoptosis: knockout mice lack apoptotic defects, and instead BCL-G binds components of the TRAPP complex, implicating it in intracellular protein trafficking [PMID:23059823]. In the gut epithelium BCL-G supports the stability of a mucin scaffolding network, and its loss accelerates colitis-associated colorectal cancer [PMID:31296963], while in intestinal epithelial cells it acts as an immunoregulator that shapes secretion of the chemokines CCL5 and CCL20, with its own expression driven by STAT1, NF-κB/p65, and the SWI/SNF remodellers BRM and BRG1 [PMID:31988296]. BCL-G is also an interferon-stimulated gene that restricts HIV replication [PMID:30083606]. A BCL2L14-ETV6 gene fusion drives motility, partial EMT, and paclitaxel resistance in triple-negative breast cancer cells [PMID:32321829].","teleology":[{"year":2000,"claim":"Established BCL-G as a BCL-2 family pro-apoptotic protein and defined how its two isoforms differ mechanistically, answering whether the protein engages the apoptotic machinery through canonical BH3 chemistry.","evidence":"Overexpression, co-immunoprecipitation, BH3/BH2 domain mutagenesis, and apoptosis assays in cells","pmids":["11054413"],"confidence":"High","gaps":["Endogenous (non-overexpression) apoptotic role not addressed","Functional consequence of the BCL-XL interaction at the mitochondrion not resolved","No structural basis for BH2 autorepression"]},{"year":2007,"claim":"Identified a kinase that negatively regulates BCL-G, answering how the pro-apoptotic activity of BCL-GL is restrained post-translationally.","evidence":"Pull-down with recombinant wild-type and kinase-dead MELK, immunocomplex kinase assay, and apoptosis readouts with RNAi","pmids":["17280616"],"confidence":"High","gaps":["Phosphorylation site(s) on BCL-GL not mapped","Whether phosphorylation alters BCL-XL binding unknown","In vivo relevance of MELK-BCL-G axis not tested"]},{"year":2011,"claim":"Placed BCL-G in a defined apoptotic pathway downstream of FAU/FUBI and UV stress, answering what upstream signals route through BCL-G.","evidence":"siRNA epistasis, ectopic overexpression, and apoptosis quantification in T-cell and 293T/17 lines","pmids":["21550398"],"confidence":"Medium","gaps":["Molecular link between FAU and BCL-G undefined","Single-lab genetic epistasis without biochemical mechanism","Isoform specificity not resolved"]},{"year":2012,"claim":"Reframed BCL-G from a classical apoptosis effector toward a trafficking-associated protein, answering whether the in vivo function matches the overexpression apoptosis phenotype.","evidence":"IP/mass spectrometry and yeast two-hybrid interactome, plus BCL-G knockout mouse with phenotypic assessment","pmids":["23059823"],"confidence":"Medium","gaps":["Mechanism by which BCL-G acts within the TRAPP complex unknown","Weak, BH3-independent binding to pro-survival proteins leaves apoptotic role ambiguous","Trafficking cargo/process not identified"]},{"year":2012,"claim":"Defined the tissue and subcellular distribution of endogenous BCL-G, establishing where it acts in vivo.","evidence":"Monoclonal antibody generation with western blotting, IHC, and immunofluorescence in mouse tissues","pmids":["22914326"],"confidence":"Medium","gaps":["Cytoplasmic compartment not resolved to specific organelle","Functional role in each tissue not established"]},{"year":2013,"claim":"Identified covalent modification by the ubiquitin-like MNSFβ as a positive regulator of BCL-G apoptotic and signaling output in macrophages.","evidence":"Co-transfection, MNSFβ G74A conjugation-dead mutant, siRNA, EMSA, and signaling western blots in Raw264.7 cells","pmids":["23298187"],"confidence":"Medium","gaps":["Conjugation site on BCL-G not mapped","Causal chain from MNSFβ-BCL-G to p53/COX-2 incompletely defined","Single-lab finding"]},{"year":2018,"claim":"Identified BCL-G as an interferon-stimulated gene with antiviral activity, expanding its role beyond apoptosis into innate immunity.","evidence":"Overexpression and RNAi with in vitro HIV replication assays under IFN-α2b treatment","pmids":["30083606"],"confidence":"Medium","gaps":["Mechanism of HIV restriction unknown","Stage of viral life cycle affected not defined","Single-lab in vitro evidence"]},{"year":2019,"claim":"Established a tissue-protective, tumor-suppressive role for BCL-G in the gut epithelium tied to mucin scaffolding, answering its physiological function in the GI tract.","evidence":"Bcl-G knockout mouse, colitis-associated cancer model, and label-free quantitative proteomics with IHC","pmids":["31296963"],"confidence":"High","gaps":["Molecular interaction with mucin network components not defined","How BCL-G loss accelerates tumorigenesis mechanistically unresolved"]},{"year":2020,"claim":"Defined a non-apoptotic immunoregulatory function in intestinal epithelium and mapped the transcriptional inputs controlling BCL-G expression.","evidence":"RNAi, CRISPR/Cas9, isoform-specific overexpression, chemokine secretion assays, and primary human colonic organoids with pathway inhibition","pmids":["31988296"],"confidence":"High","gaps":["Mechanism linking BCL-G to differential CCL5/CCL20 secretion unknown","Direct effector partners in chemokine regulation not identified"]},{"year":2020,"claim":"Characterized an oncogenic BCL2L14-ETV6 fusion, showing how genomic rearrangement repurposes the locus in breast cancer.","evidence":"Ectopic fusion expression, motility/invasion and paclitaxel resistance assays, gene expression analysis, and patient whole-genome sequencing","pmids":["32321829"],"confidence":"Medium","gaps":["Contribution of the BCL2L14 portion versus ETV6 to fusion activity unclear","Transcriptional targets driving the phenotype not fully defined"]},{"year":2016,"claim":"Reported a JAB1/CSN5 interaction influencing BCL-G localization and caspase-dependent apoptosis in a porcine system.","evidence":"Co-immunoprecipitation, subcellular localization, caspase activity, and apoptosis assays in porcine cells","pmids":["27542239"],"confidence":"Low","gaps":["Single Co-IP in non-human cells; relevance to human BCL-G uncertain","Caspase dependence only partially established","Not independently confirmed"]},{"year":2025,"claim":"Reported a pro-proliferative role for BCL2L14 in breast cancer linked to NF-κB phosphorylation.","evidence":"In vitro overexpression with downstream NF-κB phosphorylation readout","pmids":["40491783"],"confidence":"Low","gaps":["Single overexpression experiment with minimal mechanistic detail","Direction conflicts with tumor-suppressive role in gut; context dependence unresolved","No loss-of-function or in vivo validation"]},{"year":null,"claim":"It remains unresolved how BCL-G's apoptotic, trafficking, mucin-scaffolding, immunoregulatory, and antiviral activities are mechanistically connected, and whether they reflect distinct isoform- or tissue-specific molecular functions.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying biochemical activity defined across contexts","Isoform-specific molecular functions not delineated","No structural model of BCL-G in any complex"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,10]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,4]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[6,8]}],"complexes":[],"partners":["BCL2L1","MELK","MNSFΒ","TRAPP COMPLEX"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9BZR8","full_name":"Apoptosis facilitator Bcl-2-like protein 14","aliases":["Apoptosis regulator Bcl-G"],"length_aa":327,"mass_kda":36.6,"function":"Plays a role in apoptosis","subcellular_location":"Endomembrane system","url":"https://www.uniprot.org/uniprotkb/Q9BZR8/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BCL2L14","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BCL2L14","total_profiled":1310},"omim":[{"mim_id":"621334","title":"MICRO RNA 496; MIR496","url":"https://www.omim.org/entry/621334"},{"mim_id":"611787","title":"CYTIDINE MONOPHOSPHATE (UMP-CMP) KINASE 2, MITOCHONDRIAL; CMPK2","url":"https://www.omim.org/entry/611787"},{"mim_id":"606126","title":"BCL2-LIKE 14; BCL2L14","url":"https://www.omim.org/entry/606126"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":14.5},{"tissue":"stomach 1","ntpm":8.8},{"tissue":"testis","ntpm":29.6}],"url":"https://www.proteinatlas.org/search/BCL2L14"},"hgnc":{"alias_symbol":["BCLG","BCL-G"],"prev_symbol":[]},"alphafold":{"accession":"Q9BZR8","domains":[{"cath_id":"1.10.437.10","chopping":"18-34_136-166_240-321","consensus_level":"medium","plddt":84.0218,"start":18,"end":321}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BZR8","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BZR8-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BZR8-F1-predicted_aligned_error_v6.png","plddt_mean":62.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BCL2L14","jax_strain_url":"https://www.jax.org/strain/search?query=BCL2L14"},"sequence":{"accession":"Q9BZR8","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9BZR8.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9BZR8/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BZR8"}},"corpus_meta":[{"pmid":"17280616","id":"PMC_17280616","title":"Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family.","date":"2007","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/17280616","citation_count":159,"is_preprint":false},{"pmid":"11054413","id":"PMC_11054413","title":"Bcl-G, a novel pro-apoptotic member of the Bcl-2 family.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11054413","citation_count":135,"is_preprint":false},{"pmid":"30083606","id":"PMC_30083606","title":"CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction in humans.","date":"2018","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/30083606","citation_count":57,"is_preprint":false},{"pmid":"21550398","id":"PMC_21550398","title":"Candidate tumour suppressor Fau regulates apoptosis in human cells: an essential role for Bcl-G.","date":"2011","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/21550398","citation_count":35,"is_preprint":false},{"pmid":"32321829","id":"PMC_32321829","title":"Landscape analysis of adjacent gene rearrangements reveals BCL2L14-ETV6 gene fusions in more aggressive triple-negative breast cancer.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32321829","citation_count":33,"is_preprint":false},{"pmid":"30597231","id":"PMC_30597231","title":"Upregulation of miR-496 decreases cerebral ischemia/reperfusion injury by negatively regulating BCL2L14.","date":"2018","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/30597231","citation_count":32,"is_preprint":false},{"pmid":"31988296","id":"PMC_31988296","title":"Human BCL-G regulates secretion of inflammatory chemokines but is dispensable for induction of apoptosis by IFN-γ and TNF-α in intestinal epithelial cells.","date":"2020","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31988296","citation_count":25,"is_preprint":false},{"pmid":"23298187","id":"PMC_23298187","title":"Ubiquitin-like protein MNSFβ covalently binds to Bcl-G and enhances lipopolysaccharide/interferon γ-induced apoptosis in macrophages.","date":"2013","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/23298187","citation_count":20,"is_preprint":false},{"pmid":"23059823","id":"PMC_23059823","title":"Bcl-2 family member Bcl-G is not a proapoptotic protein.","date":"2012","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/23059823","citation_count":17,"is_preprint":false},{"pmid":"30075151","id":"PMC_30075151","title":"Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression.","date":"2018","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/30075151","citation_count":15,"is_preprint":false},{"pmid":"37031274","id":"PMC_37031274","title":"BCL-G: 20 years of research on a non-typical protein from the BCL-2 family.","date":"2023","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/37031274","citation_count":14,"is_preprint":false},{"pmid":"19524489","id":"PMC_19524489","title":"Upregulated BclG(L) expression enhances apoptosis of peripheral blood CD4+ T lymphocytes in patients with systemic lupus erythematosus.","date":"2009","source":"Clinical immunology (Orlando, Fla.)","url":"https://pubmed.ncbi.nlm.nih.gov/19524489","citation_count":14,"is_preprint":false},{"pmid":"20687224","id":"PMC_20687224","title":"Apoptosis regulators Fau and Bcl-G are down-regulated in prostate cancer.","date":"2010","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/20687224","citation_count":13,"is_preprint":false},{"pmid":"31296963","id":"PMC_31296963","title":"Loss of Bcl-G, a Bcl-2 family member, augments the development of inflammation-associated colorectal cancer.","date":"2019","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/31296963","citation_count":12,"is_preprint":false},{"pmid":"22914326","id":"PMC_22914326","title":"Detection of Bcl-2 family member Bcl-G in mouse tissues using new monoclonal antibodies.","date":"2012","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/22914326","citation_count":8,"is_preprint":false},{"pmid":"16484005","id":"PMC_16484005","title":"BH3 domain mutation of proapoptotic genes Bad, Bmf and Bcl-G is rare in transitional cell carcinomas of the urinary bladder.","date":"2006","source":"Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/16484005","citation_count":4,"is_preprint":false},{"pmid":"17557568","id":"PMC_17557568","title":"Mutational analysis of the BH3 domains of proapoptotic Bcl-2 family genes Bad, Bmf and Bcl-G in laryngeal squamous cell carcinomas.","date":"2007","source":"Tumori","url":"https://pubmed.ncbi.nlm.nih.gov/17557568","citation_count":4,"is_preprint":false},{"pmid":"27542239","id":"PMC_27542239","title":"A potential molecular model for studying apoptosis enhanced by the interaction of BCL-G with JAB1 in swine.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27542239","citation_count":3,"is_preprint":false},{"pmid":"33209886","id":"PMC_33209886","title":"Porcine ubiquitin-like protein MNSFβ promotes cell apoptosis and covalently binds to BCL-G to enhance staurosporine-induced apoptosis.","date":"2020","source":"Annals of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33209886","citation_count":1,"is_preprint":false},{"pmid":"21138691","id":"PMC_21138691","title":"[Cloning and expression of novel swine gene BCL-G(L) in E.coli and preparation of its polyclonal antibody in guinea pigs].","date":"2010","source":"Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21138691","citation_count":1,"is_preprint":false},{"pmid":"40491783","id":"PMC_40491783","title":"Integration of Bulk and Single-Cell Transcriptomics Reveals BCL2L14 as a Novel IGKC+ T Cell-Associated Therapeutic Target in Breast Cancer.","date":"2025","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/40491783","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":12917,"output_tokens":3392,"usd":0.044816,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":10892,"output_tokens":3847,"usd":0.075317,"stage2_stop_reason":"end_turn"},"total_usd":0.120133,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"BCL-G encodes two isoforms (BCL-GL and BCL-GS) via alternative splicing; BCL-GS contains only a BH3 domain while BCL-GL contains both BH2 and BH3 domains. BCL-GS-induced apoptosis depends on its BH3 domain and is suppressed by BCL-XL co-expression. BCL-XL co-immunoprecipitates with BCL-GS but not with BH3-deleted/mutated BCL-GS or with BCL-GL. Deletion of the BH2 domain from BCL-GL increases its apoptotic activity and enables co-immunoprecipitation with BCL-XL, indicating BH2 autorepresses BCL-GL. BCL-GS localizes to cytosolic organelles; BCL-GL is diffusely distributed in the cytosol.\",\n      \"method\": \"Overexpression in cells, co-immunoprecipitation, BH3 domain deletion/mutation, subcellular localization, apoptosis assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (co-IP, mutagenesis, localization, functional apoptosis assay) in the discovery paper; foundational study replicated in subsequent work\",\n      \"pmids\": [\"11054413\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MELK kinase physically interacts with BCL-GL through its amino-terminal region (pull-down assay), and BCL-GL is specifically phosphorylated by MELK in vitro (immunocomplex kinase assay). Overexpression of wild-type MELK suppresses BCL-GL-induced apoptosis, while kinase-dead MELK (D150A) does not, demonstrating that MELK's kinase activity is required to inhibit BCL-GL pro-apoptotic function.\",\n      \"method\": \"Pull-down assay with recombinant wild-type and kinase-dead MELK, immunocomplex kinase assay, TUNEL and FACS apoptosis analysis, RNAi knockdown\",\n      \"journal\": \"Breast cancer research : BCR\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — in vitro kinase assay plus mutagenesis (kinase-dead mutant) plus functional apoptosis readout in a single study\",\n      \"pmids\": [\"17280616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"FAU (encoding ubiquitin-like protein FUBI) promotes apoptosis in human T-cell lines and 293T/17 cells; prior knockdown of BCL-G expression ablates FAU-stimulated basal apoptosis, placing BCL-G downstream of FAU in the same apoptotic pathway. UV irradiation also increases BCL-G mRNA levels and BCL-G knockdown attenuates UV-induced apoptosis, implicating BCL-G as a common mediator of FAU- and UV-induced apoptosis.\",\n      \"method\": \"siRNA-mediated knockdown (FAU and BCL-G), ectopic FAU overexpression, apoptosis quantification in T-cell lines and 293T/17 cells, RT-PCR\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis via RNAi knockdown with specific apoptosis phenotype, two orthogonal perturbations (OE and KD), single lab\",\n      \"pmids\": [\"21550398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Mouse BCL-G binds only weakly to pro-survival BCL-2 family members in a BH3-domain-independent manner. Immunoprecipitation/mass spectrometry and yeast two-hybrid screening identified proteins of the transport particle protein (TRAPP) complex as BCL-G-binding partners, suggesting BCL-G has a role in intracellular protein trafficking rather than classical stress-induced apoptosis. BCL-G knockout mice show no apparent apoptotic defects.\",\n      \"method\": \"Immunoprecipitation/mass spectrometry, yeast two-hybrid screening, BCL-G knockout mouse generation, co-immunoprecipitation\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and MS interactome plus KO mouse with phenotypic readout, single lab, two orthogonal methods\",\n      \"pmids\": [\"23059823\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Ubiquitin-like protein MNSFβ covalently binds to BCL-G in mouse macrophages (Raw264.7). Co-transfection of MNSFβ and BCL-G greatly enhances LPS/IFNγ-induced apoptosis, accompanied by increased p53 expression and decreased COX-2 activity. MNSFβ G74A mutant (unable to covalently conjugate) fails to enhance apoptosis with BCL-G. The MNSFβ-BCL-G complex down-regulates ERK/AP-1 signaling, reducing COX-2 activation.\",\n      \"method\": \"Co-transfection, siRNA knockdown of MNSFβ, MNSFβ G74A mutant, apoptosis assays (TUNEL, flow cytometry), EMSA, western blot for p53/COX-2/ERK\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mutagenesis (G74A) combined with co-transfection and signaling readouts in a single lab study with multiple orthogonal methods\",\n      \"pmids\": [\"23298187\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BCL-G is highly expressed in gastrointestinal epithelial cells from early embryonic development and is dispensable for normal growth and development in mice. However, loss of BCL-G accelerates colitis-associated colorectal cancer progression. Label-free quantitative proteomics revealed that BCL-G contributes to the stability of a mucin scaffolding network in the gut epithelium.\",\n      \"method\": \"Bcl-G knockout mouse model, colitis-associated cancer model, label-free quantitative proteomics, immunohistochemistry\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mouse with defined cancer phenotype plus proteomics identification of mucin network interaction, multiple orthogonal methods\",\n      \"pmids\": [\"31296963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BCL-G is dispensable for IFN-γ/TNF-α-induced apoptosis in intestinal epithelial cells (IEC), as shown by RNAi and CRISPR/Cas9 perturbations. Instead, BCL-G depletion differentially affects secretion of inflammatory chemokines CCL5 and CCL20, revealing a non-apoptotic immunoregulatory function. Optimal BCL-G expression requires STAT1, NF-κB/p65, and SWI/SNF-associated chromatin remodellers BRM and BRG1.\",\n      \"method\": \"RNAi knockdown, CRISPR/Cas9 knockout, isoform-specific overexpression, chemokine secretion assays, primary human colonic organoids, pathway inhibition\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR KO and RNAi with specific chemokine secretion readout, multiple orthogonal perturbations including primary organoids\",\n      \"pmids\": [\"31988296\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BCL2L14-ETV6 fusion proteins (arising from cryptic adjacent gene rearrangement) induce distinct transcriptional changes compared to wild-type ETV6, enhance cell motility and invasiveness of TNBC cells, prime partial epithelial-mesenchymal transition, and confer resistance to paclitaxel treatment.\",\n      \"method\": \"Ectopic expression of fusion constructs, cell motility/invasion assays, gene expression analysis, paclitaxel resistance assays, whole-genome sequencing of patient cohorts\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional cell-based assays with ectopic fusion expression, multiple readouts, single lab\",\n      \"pmids\": [\"32321829\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BCL-G overexpression diminishes HIV replication in vitro, and RNAi to BCL-G attenuates the IFN-α2b-mediated restriction of HIV in culture, identifying BCL-G as an interferon-stimulated gene (ISG) with antiviral activity against HIV.\",\n      \"method\": \"RNA interference knockdown, BCL-G overexpression, in vitro HIV replication assay, IFN-α2b treatment\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — both gain- and loss-of-function experiments with specific viral replication readout, single lab, two orthogonal methods\",\n      \"pmids\": [\"30083606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Porcine BCL-G interacts with porcine JAB1 (CSN5); this interaction affects BCL-G subcellular distribution and significantly enhances staurosporine-induced apoptosis that is at least partially dependent on activated caspase-8, -9, and -3. The BH2 domain of BCL-G affects its subcellular localization.\",\n      \"method\": \"Co-immunoprecipitation, subcellular localization analysis, overexpression, caspase activity assays, apoptosis assays\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single co-IP with functional follow-up in porcine (non-mammalian-model) cells, single lab, ortholog relevance to human BCL-G uncertain\",\n      \"pmids\": [\"27542239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Mouse BCL-G is predominantly cytoplasmic and is expressed in mature spermatids in the testis, CD8+ conventional dendritic cells in hematopoietic tissues, and diverse epithelial cell types lining the gastrointestinal and respiratory tracts.\",\n      \"method\": \"Monoclonal antibody generation, western blotting, immunohistochemistry, immunofluorescence\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization via multiple antibody-based methods (IHC, IF, WB) with tissue-level resolution\",\n      \"pmids\": [\"22914326\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Overexpression of BCL2L14 in breast cancer cells accelerates cancer cell proliferation/progression, linked to enhanced phosphorylation of the NF-κB signaling pathway.\",\n      \"method\": \"In vitro BCL2L14 overexpression, downstream NF-κB phosphorylation assay\",\n      \"journal\": \"Journal of inflammation research\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single overexpression experiment with signaling readout, single lab, minimal mechanistic detail in abstract\",\n      \"pmids\": [\"40491783\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BCL-G (BCL2L14) is a BCL-2 family protein existing as two isoforms (BCL-GL with BH2+BH3 domains; BCL-GS with BH3 only) whose pro-apoptotic activity is mediated through its BH3 domain (interacting with BCL-XL), autorepressed by its BH2 domain in BCL-GL, and regulated by post-translational modifications including covalent conjugation by ubiquitin-like MNSFβ and phosphorylation by MELK kinase; beyond apoptosis, BCL-G plays roles in intracellular protein trafficking (via interaction with the TRAPP complex), gut epithelial homeostasis through maintaining a mucin scaffolding network, and immunomodulation through regulation of CCL5/CCL20 chemokine secretion, while also functioning as an interferon-stimulated antiviral factor.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BCL2L14 (BCL-G) is a BCL-2 family protein originally characterized as a pro-apoptotic factor but increasingly defined by non-apoptotic roles in epithelial homeostasis, immune regulation, and antiviral defense [#0, #5, #6]. It is expressed as two splice isoforms: BCL-GS, a BH3-only protein whose apoptotic activity depends on its BH3 domain and is suppressed by BCL-XL, with which it directly co-immunoprecipitates; and the longer BCL-GL, in which an additional BH2 domain autorepresses pro-apoptotic activity and blocks BCL-XL binding until removed [#0]. Its death-promoting function is gated by post-translational control — MELK kinase binds and phosphorylates BCL-GL to inhibit its apoptotic activity [#1], while covalent conjugation by the ubiquitin-like protein MNSF\\u03b2 enhances LPS/IFN\\u03b3-induced apoptosis through down-regulation of ERK/AP-1 and COX-2 signaling [#4]. In vivo, however, BCL-G is dispensable for stress-induced apoptosis: knockout mice lack apoptotic defects, and instead BCL-G binds components of the TRAPP complex, implicating it in intracellular protein trafficking [#3]. In the gut epithelium BCL-G supports the stability of a mucin scaffolding network, and its loss accelerates colitis-associated colorectal cancer [#5], while in intestinal epithelial cells it acts as an immunoregulator that shapes secretion of the chemokines CCL5 and CCL20, with its own expression driven by STAT1, NF-\\u03baB/p65, and the SWI/SNF remodellers BRM and BRG1 [#6]. BCL-G is also an interferon-stimulated gene that restricts HIV replication [#8]. A BCL2L14-ETV6 gene fusion drives motility, partial EMT, and paclitaxel resistance in triple-negative breast cancer cells [#7].\"\n,\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established BCL-G as a BCL-2 family pro-apoptotic protein and defined how its two isoforms differ mechanistically, answering whether the protein engages the apoptotic machinery through canonical BH3 chemistry.\",\n      \"evidence\": \"Overexpression, co-immunoprecipitation, BH3/BH2 domain mutagenesis, and apoptosis assays in cells\",\n      \"pmids\": [\"11054413\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous (non-overexpression) apoptotic role not addressed\", \"Functional consequence of the BCL-XL interaction at the mitochondrion not resolved\", \"No structural basis for BH2 autorepression\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified a kinase that negatively regulates BCL-G, answering how the pro-apoptotic activity of BCL-GL is restrained post-translationally.\",\n      \"evidence\": \"Pull-down with recombinant wild-type and kinase-dead MELK, immunocomplex kinase assay, and apoptosis readouts with RNAi\",\n      \"pmids\": [\"17280616\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Phosphorylation site(s) on BCL-GL not mapped\", \"Whether phosphorylation alters BCL-XL binding unknown\", \"In vivo relevance of MELK-BCL-G axis not tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Placed BCL-G in a defined apoptotic pathway downstream of FAU/FUBI and UV stress, answering what upstream signals route through BCL-G.\",\n      \"evidence\": \"siRNA epistasis, ectopic overexpression, and apoptosis quantification in T-cell and 293T/17 lines\",\n      \"pmids\": [\"21550398\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular link between FAU and BCL-G undefined\", \"Single-lab genetic epistasis without biochemical mechanism\", \"Isoform specificity not resolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Reframed BCL-G from a classical apoptosis effector toward a trafficking-associated protein, answering whether the in vivo function matches the overexpression apoptosis phenotype.\",\n      \"evidence\": \"IP/mass spectrometry and yeast two-hybrid interactome, plus BCL-G knockout mouse with phenotypic assessment\",\n      \"pmids\": [\"23059823\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which BCL-G acts within the TRAPP complex unknown\", \"Weak, BH3-independent binding to pro-survival proteins leaves apoptotic role ambiguous\", \"Trafficking cargo/process not identified\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined the tissue and subcellular distribution of endogenous BCL-G, establishing where it acts in vivo.\",\n      \"evidence\": \"Monoclonal antibody generation with western blotting, IHC, and immunofluorescence in mouse tissues\",\n      \"pmids\": [\"22914326\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cytoplasmic compartment not resolved to specific organelle\", \"Functional role in each tissue not established\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified covalent modification by the ubiquitin-like MNSF\\u03b2 as a positive regulator of BCL-G apoptotic and signaling output in macrophages.\",\n      \"evidence\": \"Co-transfection, MNSF\\u03b2 G74A conjugation-dead mutant, siRNA, EMSA, and signaling western blots in Raw264.7 cells\",\n      \"pmids\": [\"23298187\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Conjugation site on BCL-G not mapped\", \"Causal chain from MNSF\\u03b2-BCL-G to p53/COX-2 incompletely defined\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified BCL-G as an interferon-stimulated gene with antiviral activity, expanding its role beyond apoptosis into innate immunity.\",\n      \"evidence\": \"Overexpression and RNAi with in vitro HIV replication assays under IFN-\\u03b12b treatment\",\n      \"pmids\": [\"30083606\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of HIV restriction unknown\", \"Stage of viral life cycle affected not defined\", \"Single-lab in vitro evidence\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established a tissue-protective, tumor-suppressive role for BCL-G in the gut epithelium tied to mucin scaffolding, answering its physiological function in the GI tract.\",\n      \"evidence\": \"Bcl-G knockout mouse, colitis-associated cancer model, and label-free quantitative proteomics with IHC\",\n      \"pmids\": [\"31296963\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular interaction with mucin network components not defined\", \"How BCL-G loss accelerates tumorigenesis mechanistically unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined a non-apoptotic immunoregulatory function in intestinal epithelium and mapped the transcriptional inputs controlling BCL-G expression.\",\n      \"evidence\": \"RNAi, CRISPR/Cas9, isoform-specific overexpression, chemokine secretion assays, and primary human colonic organoids with pathway inhibition\",\n      \"pmids\": [\"31988296\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking BCL-G to differential CCL5/CCL20 secretion unknown\", \"Direct effector partners in chemokine regulation not identified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Characterized an oncogenic BCL2L14-ETV6 fusion, showing how genomic rearrangement repurposes the locus in breast cancer.\",\n      \"evidence\": \"Ectopic fusion expression, motility/invasion and paclitaxel resistance assays, gene expression analysis, and patient whole-genome sequencing\",\n      \"pmids\": [\"32321829\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Contribution of the BCL2L14 portion versus ETV6 to fusion activity unclear\", \"Transcriptional targets driving the phenotype not fully defined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Reported a JAB1/CSN5 interaction influencing BCL-G localization and caspase-dependent apoptosis in a porcine system.\",\n      \"evidence\": \"Co-immunoprecipitation, subcellular localization, caspase activity, and apoptosis assays in porcine cells\",\n      \"pmids\": [\"27542239\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single Co-IP in non-human cells; relevance to human BCL-G uncertain\", \"Caspase dependence only partially established\", \"Not independently confirmed\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Reported a pro-proliferative role for BCL2L14 in breast cancer linked to NF-\\u03baB phosphorylation.\",\n      \"evidence\": \"In vitro overexpression with downstream NF-\\u03baB phosphorylation readout\",\n      \"pmids\": [\"40491783\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single overexpression experiment with minimal mechanistic detail\", \"Direction conflicts with tumor-suppressive role in gut; context dependence unresolved\", \"No loss-of-function or in vivo validation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how BCL-G's apoptotic, trafficking, mucin-scaffolding, immunoregulatory, and antiviral activities are mechanistically connected, and whether they reflect distinct isoform- or tissue-specific molecular functions.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying biochemical activity defined across contexts\", \"Isoform-specific molecular functions not delineated\", \"No structural model of BCL-G in any complex\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 4]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [6, 8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"BCL2L1\", \"MELK\", \"MNSF\\u03b2\", \"TRAPP complex\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":7,"faith_total":7,"faith_pct":100.0}}